Merck
Melanoma vaccine cuts recurrence and death risk by 42 percent in trial
A bespoke messenger RNA vaccine developed by Moderna and Merck has shown a dramatic reduction in melanoma recurrence when paired with established immunotherapy.
Moderna and Merck mRNA melanoma vaccine cuts recurrence risk by 42 percent
A personalized mRNA cancer vaccine developed by Moderna and Merck significantly reduces melanoma recurrence risks, according to landmark Phase 3 clinical trial results.
Moderna skin cancer vaccine trial shows promise in preventing recurrence
A phase 3 clinical trial evaluating Moderna and Merck's personalized mRNA skin cancer vaccine has met its primary goals in delaying recurrence.
Moderna's melanoma vaccine meets primary goal, sparks growth hopes
Moderna's personalized mRNA cancer vaccine Intismeran met its primary endpoint in a late-stage trial combined with Merck's Keytruda, sparking a major market rally.
FDA approves Lipfendra as first oral PCSK9 inhibitor for high cholesterol
Merck’s Lipfendra has received FDA approval as the first oral PCSK9 inhibitor, offering a daily pill option to help lower LDL cholesterol levels.